RESEARCH-USE BIOSIMILAR ANTIBODY
Bepranemab
Monoclonal antibody · IgG4
Bepranemab is a humanized IgG4 monoclonal antibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease.
TARGETMAPT
YMonoclonal antibody
CATALOGSC-BS-721
CATALOG NUMBERSC-BS-721
MOLECULAR WEIGHTApprox. 145.52 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Bepranemab is a humanized IgG4 monoclonal antibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease.
Bepranemab is a recombinant research-use antibody directed against MAPT.